Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

MRUS

Merus N.V

Dec 22 • 04:00PM ET

96.95

-0.06 -0.06 %

Healthcare • Biotechnology • Netherlands • NASD

Peers: BNTX ASND FATE AFMD KRYS CLLS ALLO ADAP NBP ADCT

| Held by: VHT VT MSSM CHNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.33	Insider Own	58.40%	Shs Outstand	75.84M	Perf Week	0.13%
Market Cap	7.35B	Forward P/E	-	EPS next Y	-4.93	Insider Trans	1.04%	Shs Float	31.55M	Perf Month	1.01%
Enterprise Value	6.73B	PEG	-	EPS next Q	-1.11	Inst Own	87.66%	Short Float	4.98%	Perf Quarter	42.11%
Income	-381.14M	P/S	129.90	EPS this Y	-69.32%	Inst Trans	-7.37%	Short Ratio	0.64	Perf Half Y	79.11%
Sales	56.61M	P/B	9.49	EPS next Y	13.04%	ROA	-43.59%	Short Interest	1.57M	Perf YTD	130.56%
Book/sh	10.22	P/C	11.56	EPS next 5Y	-3.71%	ROE	-51.57%	52W High	97.14 -0.20%	Perf Year	128.44%
Cash/sh	8.38	P/FCF	-	EPS past 3/5Y	-24.70% -8.04%	ROIC	-48.58%	52W Low	33.19 192.11%	Perf 3Y	630.05%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-9.72% 3.02%	Gross Margin	-	Volatility	0.21% 0.22%	Perf 5Y	471.98%
Dividend TTM	-	EV/Sales	118.88	EPS Y/Y TTM	-36.57%	Oper. Margin	-655.80%	ATR (14)	0.31	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.97	Sales Y/Y TTM	57.54%	Profit Margin	-673.31%	RSI (14)	71.57	Recom	2.75
Dividend Gr. 3/5Y	- -	Current Ratio	7.97	EPS Q/Q	13.77%	SMA20	0.52%	Beta	1.07	Target Price	97.00
Payout	-	Debt/Eq	0.02	Sales Q/Q	3.21%	SMA50	1.32%	Rel Volume	0.20	Prev Close	97.01
Employees	260	LT Debt/Eq	0.01	Earnings	Oct 30	SMA200	45.04%	Avg Volume	2.48M	Price	96.95
IPO	May 19, 2016	Option/Short	Yes / Yes	EPS/Sales Surpr.	6.81% 30.78%	Trades		Volume	501,179	Change	-0.06%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-17-25	Initiated	Barclays	Overweight	$112
Aug-25-25	Initiated	Alliance Global Partners	Buy	$90
Feb-13-25	Initiated	Piper Sandler	Overweight	$84
Feb-07-25	Initiated	Wells Fargo	Overweight	$91
Nov-21-24	Initiated	Goldman	Buy	$73
Oct-24-24	Initiated	UBS	Buy	$72
Mar-28-24	Initiated	Truist	Buy	$69
Mar-04-24	Reiterated	Needham	Buy	$42 → $65
Nov-02-23	Initiated	Canaccord Genuity	Buy	$45
Aug-21-23	Initiated	TD Cowen	Outperform
Aug-02-22	Initiated	Stifel	Buy	$38
Feb-11-22	Initiated	BMO Capital Markets	Outperform	$45
Feb-10-22	Initiated	Needham	Buy	$45
Nov-17-21	Resumed	Guggenheim	Buy	$44
Jun-07-21	Upgrade	Citigroup	Neutral → Buy	$24 → $31
Apr-08-21	Initiated	William Blair	Outperform
Mar-16-21	Initiated	SVB Leerink	Outperform	$33
Jun-26-20	Initiated	H.C. Wainwright	Buy	$23
May-27-20	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16
Nov-20-19	Resumed	Guggenheim	Buy

Show Previous Ratings

Dec-16-25 01:17PM	Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B (PR Newswire)
Dec-12-25 01:36AM	Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period (Business Wire)
Dec-04-25 02:02PM	How Stock Of The Day Genmab Is Leveraging An $8 Billion Deal To Stoke Its Next Chapter (Investor's Business Daily)
01:58PM	Merus N.V. (MRUS): A Bull Case Theory (Insider Monkey)
Nov-17-25 07:00AM	Merus and Halozyme Enter Global Collaboration and License Agreement to Develop Subcutaneous Formulation of Petosemtamab (PR Newswire)
01:55PM	Loading…
Nov-12-25 01:55PM	Halper Sadeh LLC Encourages HSII, MRUS, ATXS Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Nov-05-25 12:35PM	Halper Sadeh LLC Encourages TIPT, MRUS, PBBK Shareholders to Contact the Firm to Discuss Their Rights (PR Newswire)
Oct-24-25 10:00AM	Merus' Interim Data on Petosemtamab in Metastatic Colorectal Cancer Demonstrates Monotherapy Activity and Robust Response Rate in Combination with FOLFOX/FOLFIRI with Well Tolerated Safety (GlobeNewswire)
Oct-14-25 07:30AM	Merus Announces Publication of an Abstract on Petosemtamab in Metastatic Colorectal Cancer at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-13-25 12:00PM	Merus Announces Petosemtamab in Metastatic Colorectal Cancer Abstract Selected for Plenary Session Oral Presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Oct-06-25 09:50AM	GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal (Zacks)
Oct-02-25 04:55PM	Merus (MRUS) Gains Validation With Zenocutuzumab Approval, Barclays Sees Growth Potential (Insider Monkey)
Sep-30-25 03:38PM	Merus (MRUS) Soars to New High on Genmab Merger at 41% Premium (Insider Monkey)
Sep-29-25 04:25PM	Genmab Strikes $8 Billion Deal To Acquire Cancer-Focused Merus (Investor's Business Daily) +35.97%
10:38AM	Stock Market Today: Stocks mixed as Trump meets with lawmakers in last ditch to avert government shutdown (TheStreet)
10:15AM	Loading…
10:15AM	Genmab Makes $8 Billion Bet On Merus With Potential Cancer Breakthrough (Benzinga)
09:46AM	EA downgraded, AppLovin initiated: Wall Street's top analyst calls (The Fly)
07:36AM	This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired. (Barrons.com)
06:07AM	Premarket movers: Merus, GSK, Novo Nordisk (MarketWatch)
05:34AM	Months after cancer drug trial, Merus agrees to be bought at 41% premium (MarketWatch)
01:14AM	Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model (Business Wire)
Sep-15-25 12:15PM	Top 3 Biotech Stocks to Watch According to BofA Global Research (Investing.com)
Sep-09-25 02:22PM	Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade. (Barrons.com)
Aug-28-25 08:00AM	Merus to Present at the 2025 Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-06-25 08:00AM	Merus to Present at the Canaccord Genuity 45th Annual Growth Conference (GlobeNewswire)
Aug-05-25 06:35PM	Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:07PM	Merus Announces Financial Results for the Second Quarter 2025 and Provides Business Update (GlobeNewswire)
Aug-04-25 05:20PM	BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates (Zacks)
04:01PM	Merus N.V. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-01-25 06:46AM	Bank of America Securities Maintained a Buy Rating on Merus N.V (MRUS) (Insider Monkey)
10:41AM	Loading…
Jul-11-25 10:41AM	MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success (Zacks)
Jul-09-25 12:55AM	Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III (Insider Monkey)
Jun-05-25 09:45AM	Merus CEO: We're really optimistic about the potential for our drug in head and neck cancer (CNBC TV)
05:51AM	Why Merus N.V. (MRUS) Crashed On Wednesday (Insider Monkey)
Jun-04-25 12:13AM	Merus N.V. Announces Pricing of Public Offering of Common Shares (GlobeNewswire) -7.75%
Jun-03-25 04:05PM	Merus N.V. Announces Proposed Public Offering of Common Shares (GlobeNewswire) +6.65%
May-29-25 06:54AM	ASCO25: Merus wins in head-to-head with Bicara for head and neck cancer (Clinical Trials Arena) +10.72%
May-27-25 08:00AM	Merus to Present at Upcoming Investor Conferences (GlobeNewswire) -7.87%
May-25-25 04:00PM	BofA Maintains Buy Rating on Merus (MRUS), Lifts PT (Insider Monkey)
04:26AM	Merus (MRUS) Price Target Raised at BMO After Positive Phase 2 Data (Insider Monkey)
May-23-25 07:00PM	Merus updates on Petosemtamab+Pembrolizumab data in HNSCC (TipRanks) +32.55% -7.87%
10:15AM	Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics (Investor's Business Daily)
May-22-25 05:30PM	Merus' Petosemtamab with Pembrolizumab Interim Data Demonstrates Robust Efficacy and Durability in 1L PD-L1+ r/m HNSCC (GlobeNewswire)
May-15-25 08:00AM	Merus Announces the Journal Publication of Petosemtamab Mechanism of Action (GlobeNewswire)
May-09-25 10:23AM	Merus N.V. (MRUS): Among the Best Cancer Stocks to Invest in for Long-Term Gain (Insider Monkey)
May-08-25 08:00AM	Merus to Present at BofA Securities 2025 Health Care Conference (GlobeNewswire) +8.47%
May-07-25 06:35PM	Merus N.V. (MRUS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Merus Announces Financial Results for the First Quarter 2025 and Provides Business Update (GlobeNewswire)
10:00AM	Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline (Zacks)
Apr-25-25 09:40AM	Merus Will Have a Best-in-Class Treatment for Head and Neck Cancer, Analysts Say (Barrons.com)
Apr-23-25 10:00AM	Merus Announces Abstract Accepted for Presentation at the 2025 ASCO Annual Meeting (GlobeNewswire)
Apr-17-25 11:02PM	Is Merus (NASDAQ:MRUS) the Best High Short Interest Stock to Buy Now? (Insider Monkey)
Apr-10-25 08:17AM	Strength Seen in BioMarin (BMRN): Can Its 6.3% Jump Turn into More Strength? (Zacks)
Apr-07-25 04:34AM	Merus: Riding The Bispecific Wave In Oncology (Seeking Alpha)
Apr-01-25 08:00AM	Merus to Participate in a Fireside Chat at the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire) -5.92%
Mar-27-25 07:30AM	Franklin Biotechnology Discovery Fund Q4 2024 Commentary (SeekingAlpha)
Feb-27-25 07:05PM	Merus N.V. (MRUS) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:10PM	Merus Announces Financial Results for the Fourth Quarter and Full Year 2024 and Provides Business Update (GlobeNewswire)
Feb-25-25 08:00AM	Merus to Present at Upcoming Investor Conferences (GlobeNewswire) -5.03%
Feb-18-25 08:00AM	Petosemtamab granted Breakthrough Therapy designation by the U.S. FDA for 1L PD-L1 positive head and neck squamous cell carcinoma (GlobeNewswire) +5.15%
Feb-13-25 08:00AM	Merus to Present at Citi's 2025 Virtual Oncology Leadership Summit (GlobeNewswire)
Feb-05-25 05:00PM	New England Journal of Medicine Publishes: Efficacy of Zenocutuzumab in NRG1 Fusion-Positive Cancer (GlobeNewswire)
Jan-17-25 11:08AM	Merus N.V. (MRUS): The Biotech Stock with Biggest Upside Potential (Insider Monkey)
Jan-12-25 08:04PM	Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs (GlobeNewswire)
Jan-07-25 03:05PM	Jim Cramer Says Merus (MRUS) Still Very Speculative (Insider Monkey)
Dec-16-24 04:01PM	Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC (GlobeNewswire)
Dec-10-24 12:07PM	Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy (Insider Monkey)
Dec-07-24 01:30AM	Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC (GlobeNewswire)
Dec-05-24 02:49PM	Merus Scores Its First FDA Approval For Lung Cancer Drug (Benzinga)
11:35AM	Merus Bizengri granted FDA accelerated approval to treat NRG1+ cancers (Clinical Trials Arena)
Dec-04-24 08:35PM	Lightning Round: Take some Sterling Infrastructure off the table, let the rest run, says Jim Cramer (CNBC TV)
04:55PM	Merus Announces FDA Approval of BIZENGRI (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study (GlobeNewswire)
06:45AM	Merus price target lowered to $109 from $111 at Guggenheim (TipRanks)
Dec-02-24 12:47PM	Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline (Benzinga) +8.23%
08:00AM	Merus and Partner Therapeutics Announce License Agreement for the U.S. Commercialization of Zenocutuzumab in NRG1 Fusion-Positive Cancer (GlobeNewswire)
Dec-01-24 11:05AM	Merus Announces Publication of an Abstract on Petosemtamab as 2L+ treatment of r/m HNSCC at the ESMO Asia Congress 2024 (GlobeNewswire)
Nov-23-24 10:47AM	Merus NV (MRUS): Among the Most Promising Cancer Stocks According to Hedge Funds (Insider Monkey)
Nov-15-24 02:08AM	PDS Biotechnology Corp (PDSB) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com) -6.20%
Nov-13-24 10:48AM	Is Merus N.V. (MRUS) Top Performing European Stock Heading into 2025? (Insider Monkey)
Nov-06-24 04:01PM	Merus to Present at Upcoming Investor Conferences (GlobeNewswire)
Nov-05-24 09:15AM	FDA delays decision on Merus' first-in-class cancer drug by 3 months (FierceBiotech.com)
06:30AM	Merus Receives FDA extension of PDUFA for zenocutuzumab (GlobeNewswire)
Oct-31-24 09:25AM	Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:08AM	Merus Announces Financial Results for the Third Quarter 2024 and Provides Business Update (GlobeNewswire)
Sep-30-24 08:00AM	Merus Announces First Patient Dosed in LiGeR-HN1, a Phase 3 Trial Evaluating Petosemtamab in Combination with Pembrolizumab in 1L r/m HNSCC (GlobeNewswire)
Sep-18-24 10:11AM	TimesSquare Capital Management U.S. Small Cap Growth Strategy Established a Position in Merus N.V. (MRUS) (Insider Monkey)
Sep-17-24 09:00AM	Merus Announces Abstract Accepted for Presentation at the ESMO Asia Congress 2024 (GlobeNewswire)
Sep-14-24 05:15PM	Merus NV (MRUS): Short Seller Sentiment is Bearish on This Cancer Stock (Insider Monkey)
Aug-30-24 01:15AM	Merus NV (MRUS): Top ADR Stock According to Hedge Funds (Insider Monkey)
Aug-12-24 04:37PM	Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates (PR Newswire)
Aug-06-24 08:00AM	Merus to Present at Canaccord Genuity's 44th Annual Growth Conference (GlobeNewswire)
Aug-01-24 05:30PM	Merus N.V. (MRUS) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:10PM	Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update (GlobeNewswire)
Jul-29-24 10:00AM	Merus N.V. (MRUS) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Jul-24-24 07:00AM	Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC (GlobeNewswire)
Jul-08-24 08:00AM	Merus Announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 2L CRC (GlobeNewswire)
Jul-01-24 08:00AM	Merus Appoints Fabian Zohren M.D., Ph.D., as Chief Medical Officer (GlobeNewswire) -7.98%
Jun-03-24 02:30PM	Merus' MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO Annual Meeting (GlobeNewswire)
Jun-02-24 12:30PM	Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO Annual Meeting (GlobeNewswire)
May-29-24 09:30PM	Merus Announces Pricing of Upsized Public Offering of Common Shares (GlobeNewswire) +6.11%

Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors. The company was founded by Ton Logtenberg and Hennie Hoogenboom on June 16, 2003 and is headquartered in Utrecht, the Netherlands.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GENMAB A/S	10% Owner	Dec 18 '25	Buy	97.00	212,177	20,581,169	71,946,801	Dec 22 05:15 PM
GENMAB A/S	10% Owner	Dec 19 '25	Buy	97.00	66,264	6,427,608	72,013,065	Dec 22 05:15 PM
GENMAB A/S	10% Owner	Dec 17 '25	Buy	97.00	150,795	14,627,115	71,734,624	Dec 18 05:54 PM
GENMAB A/S	10% Owner	Dec 16 '25	Buy	97.00	120,752	11,712,944	71,583,829	Dec 18 05:54 PM
Shuman Harry	VP Controller, PAO	Nov 26 '25	Option Exercise	21.69	1,700	36,875	12,702	Dec 10 05:45 PM
Shuman Harry	VP Controller, PAO	Nov 26 '25	Sale	96.10	1,700	163,370	11,002	Dec 10 05:45 PM
Shuman Harry	VP Controller, PAO	Nov 25 '25	Sale	95.92	8,300	796,136	11,002	Nov 28 04:05 PM
Silverman Peter B.	COO & GC	Jul 17 '25	Option Exercise	24.43	25,000	610,750	25,000	Jul 18 04:05 PM
Silverman Peter B.	COO & GC	Jul 17 '25	Sale	60.00	25,000	1,500,000	0	Jul 18 04:05 PM
Silverman Peter B.	Officer	Jul 17 '25	Proposed Sale	60.00	25,000	1,500,087		Jul 17 01:06 PM
Silverman Peter B.	COO & GC	Jul 10 '25	Option Exercise	18.61	16,805	312,741	16,805	Jul 11 04:09 PM
Silverman Peter B.	COO & GC	Jul 09 '25	Option Exercise	18.61	6,695	124,594	6,695	Jul 11 04:09 PM
Silverman Peter B.	COO & GC	Jul 10 '25	Sale	55.00	16,805	924,275	0	Jul 11 04:09 PM
Silverman Peter B.	COO & GC	Jul 09 '25	Sale	55.00	6,695	368,225	0	Jul 11 04:09 PM
Silverman Peter B.	Officer	Jul 10 '25	Proposed Sale	55.00	16,805	924,313		Jul 10 04:27 PM
Silverman Peter B.	Officer	Jul 09 '25	Proposed Sale	55.00	6,695	368,240		Jul 09 04:03 PM
Silverman Peter B.	COO & GC	Jun 20 '25	Option Exercise	18.61	34,000	632,740	34,000	Jun 24 04:00 PM
Silverman Peter B.	COO & GC	Jun 20 '25	Sale	52.76	34,000	1,793,840	0	Jun 24 04:00 PM
Silverman Peter B.	Officer	Jun 20 '25	Proposed Sale	52.76	34,000	1,793,741		Jun 20 03:18 PM
Lundberg Sven Ante	President, CEO & PEO	Apr 17 '25	Option Exercise	13.40	30,297	405,894	30,297	Apr 21 04:05 PM
Shuman Harry	VP Controller, PAO	Mar 21 '25	Sale	48.50	4,000	193,990	11,002	Mar 25 04:10 PM
Shuman Harry	VP Controller, PAO	Jan 01 '25	Option Exercise	0.00	5,000	0	12,002	Mar 25 04:05 PM
Lundberg Sven Ante	President, CEO & PEO	Feb 13 '25	Option Exercise	24.43	16,372	399,968	40,601	Feb 18 05:43 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MRUS

Merus N.V

Upgrade your FINVIZ experience